These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2816859)

  • 1. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI; Bosso J; Randolph L
    Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
    Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
    Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
    Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
    J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
    Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
    Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.
    Caumo DTM; Geyer LB; Teixeira AR; Barreto SSM
    Braz J Otorhinolaryngol; 2017; 83(4):464-474. PubMed ID: 27894912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
    Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
    J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.
    Stavroulaki P; Vossinakis IC; Dinopoulou D; Doudounakis S; Adamopoulos G; Apostolopoulos N
    Arch Otolaryngol Head Neck Surg; 2002 Feb; 128(2):150-5. PubMed ID: 11843723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of aminoglycoside antibiotic-induced hearing loss.
    Brummett RE; Morrison RB
    Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):406-10. PubMed ID: 2317321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
    Zettner EM; Gleser MA
    Otolaryngol Head Neck Surg; 2018 Nov; 159(5):887-894. PubMed ID: 29914288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
    Handelsman JA; Nasr SZ; Pitts C; King WM
    Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside induced ototoxicity in patients with cystic fibrosis.
    Mulherin D; Fahy J; Grant W; Keogan M; Kavanagh B; FitzGerald M
    Ir J Med Sci; 1991 Jun; 160(6):173-5. PubMed ID: 1752740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies.
    Fausti SA; Rappaport BZ; Schechter MA; Frey RH; Ward TT; Brummett RE
    Am J Otolaryngol; 1984; 5(3):177-82. PubMed ID: 6742338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for aminoglycoside auditory toxicity in the old.
    Cheung R; Clark P; Nicholson PW; Deshmukh AA; O'Neill CJ; Dobbs SM; Dobbs RJ
    Br J Clin Pharmacol; 1990 Jul; 30(1):1-11. PubMed ID: 2390421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal dialysis.
    Warady BA; Reed L; Murphy G; Kastetter S; Karlsen E; Alon U; Hellerstein S
    Pediatr Nephrol; 1993 Apr; 7(2):178-81. PubMed ID: 8476714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
    Veenstra DL; Harris J; Gibson RL; Rosenfeld M; Burke W; Watts C
    Genet Med; 2007 Oct; 9(10):695-704. PubMed ID: 18073583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD.
    Tokgoz B; Somdas MA; Ucar C; Kocyigit I; Unal A; Sipahioglu MH; Oymak O; Utas C
    Ren Fail; 2010 Jan; 32(2):179-84. PubMed ID: 20199179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity.
    Fausti SA; Henry JA; Schaffer HI; Olson DJ; Frey RH; McDonald WJ
    J Infect Dis; 1992 Jun; 165(6):1026-32. PubMed ID: 1583319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycoside ototoxicity susceptibility in cystic fibrosis.
    Mulrennan SA; Helm J; Thomas RB; Dodd M; Jones A; Webb K
    Thorax; 2009 Mar; 64(3):271-2. PubMed ID: 19252031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.